Press Releases

Upcoming Events

European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Saturday, April 21 - Tuesday, April 24

Madrid, Spain

Clinical Leader Forum
Wednesday, May 09 - Thursday, May 10

Philadelphia, PA

American Society for Microbiology (ASM) Microbe 2018
Thursday, June 07 - Monday, June 11

Atlanta, GA

> See all Events
April 19, 2018

The awards program recognizes entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. Drs. Burns, Xerri and Pevear were selected as finalists by a panel of independent judges. Award winners will be announced at a special gala event on June 14, 2018 at the Kimmel Center for the Performing Arts.

April 12, 2018

Fourteen poster presentations, including four oral sessions, will feature VenatoRx's lead clinical antibacterial candidate, cefepime/VNRX-5133, at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain. In addition, VenatoRx’s President and CEO, Christopher J. Burns, Ph.D., will present a brief overview about the Company’s R&D pipeline during Pipeline Corner on April 23, 2013 beginning at 12:30pm CET in Hall Y.

March 19, 2018

President and CEO, Christopher J. Burns, Ph.D., will present the Company's lead clinical antibacterial candidate, VNRX-5133, during the First-Time Disclosure of Clinical Candidates Symposium at the American Chemical Society (ACS) National Meeting on Wednesday, March 21, 2018 at 3:15pm CT. The oral presentation is entitled, “Discovery of VNRX-5133: A broad-spectrum serine- and metallo-beta-lactamase inhibitor (BLI) for carbapenem-resistant bacterial infections (“superbugs”).”

January 04, 2018

The funding will support discovery and preclinical development of a novel, first-in-class antibiotic for biodefense applications. The project derives from the company’s proprietary platform of non-beta-lactam penicillin binding protein inhibitors (PBPis).

January 03, 2018

The FDA granted VenatoRx's lead antibiotic program, VNRX-5133, an injectable broad-spectrum beta-lactamase inhibitor combined with a marketed beta-lactam antibiotic, both the Qualified Infectious Disease Product (QIDP) and Fast Track designations. The designations were granted for both complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

July 27, 2017

The funding will be used to support discovery and preclinical development of a new class of antibiotic that circumvents beta-lactam antibiotic resistance, but with the same safe and effective mechanism of action of beta-lactams.

July 25, 2017

Proceeds will be used to advance the company’s portfolio, including lead product candidate VNRX-5133 for multi-drug resistant (MDR) gram-negative infections.

September 12, 2016

Dr. Diem is Senior Vice President, Business and Corporate Development at Medgenics, heading all business and corporate development activities for the company.

Archive: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010